Patent: 8,828,401
✉ Email this page to a colleague
Summary for Patent: 8,828,401
Title: | Cytotoxic peptides and antibody drug conjugates thereof |
Abstract: | The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer. |
Inventor(s): | Doroski; Matthew David (Mystic, CT), Maderna; Andreas (Stony Point, NY), O\'Donnell; Christopher John (Mystic, CT), Subramanyam; Chakrapani (South Glastonburty, CT), Vetelino; Beth (North Stonington, CT), Dushin; Russell George (Old Lyme, CT), Strop; Pavel (San Mateo, CA), Graziani; Edmund Idris (Chestnut Ridge, NY) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 13/670,612 |
Patent Claims: | see list of patent claims |
Details for Patent 8,828,401
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-11-17 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-11-17 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-11-17 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-11-17 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2031-11-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |